Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 55 points (0.3%) at 16,661 as of Tuesday, May 27, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,943 issues advancing vs. 1,024 declining with 173 unchanged. The Health Care sector currently sits up 1.4% versus the S&P 500, which is up 0.5%. Top gainers within the sector include Isis Pharmaceuticals ( ISIS), up 7.7%, Alnylam Pharmaceuticals ( ALNY), up 6.0%, Incyte ( INCY), up 3.1%, Vertex Pharmaceuticals ( VRTX), up 2.6% and Biogen Idec ( BIIB), up 1.9%. On the negative front, top decliners within the sector include Edwards Lifesciences ( EW), down 2.2%, AstraZeneca ( AZN), down 1.0%, Baxter International ( BAX), down 0.7% and Thermo Fisher Scientific ( TMO), down 0.5%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Health Care sector higher today. As of noon trading, Regeneron Pharmaceuticals is up $6.99 (2.4%) to $304.76 on light volume. Thus far, 330,620 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $298.65-$307.09 after having opened the day at $299.54 as compared to the previous trading day's close of $297.77. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $29.4 billion and is part of the drugs industry. Shares are up 8.2% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold. TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow. Get the full Regeneron Pharmaceuticals Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.